Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary

Next Previous
Trial Profile

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temsirolimus (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms GOG-0268

Most Recent Events

  • 13 Oct 2022 Results estimating the 12-month progression-free survival (PFS) for carboplatin/paclitaxel plus temsirolimus in women with newly diagnosed clear cell ovarian cancer (CCOC), compared to historical controls in this patient population, published in the Gynecologic Oncology
  • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
  • 23 Nov 2015 Status changed from active, no longer recruiting to completed as reported by clinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top